Patent US4765987A successfully refreshed from Google Patents.
US4765987A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Artificial surfactants, pharmaceutical compositions containing them and use thereof
Assignee: Institut Servier de Medecine Translationnelle SARL
•
Filing: 1986-08-25
•
Granted: 1988-08-23
•
Expires: 2006-08-25
Abstract
Abstract New artificial surfactants composed of dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine and soya lecithin and pharmaceutical compositions containing them, which can be used to replace deficient endogenous pulmonary surfactant.
Inventors
- 👤 Frederic Bonte
- 👤 Michel Dehan
- 👤 Alain Le Ridant
- 👤 Francis Puisieux
- 👤 Christiane C. Taupin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 23:02
CPC Classifications
C; C11; C11D; C11D1/00; C11D1/88; C11D1/886; A; A61; A61K; A61K31/00; A61K31/66; A61K31/683; A61K31/685; A61K9/00; A61K9/0012; A61K9/007; A61K9/0082; A61K9/10; A61K9/127; A61P; A61P11/00; Y; Y10; Y10S; Y10S436/00; Y10S436/829; Y10S516/00; Y10S516/01; Y10S516/06; Y10T; Y10T428/00; Y10T428/29; Y10T428/2982; Y10T428/2984
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
62 words
Artificial surfactant characterised in that it consists essentially of a ternary mixture of: (1) from 10 to 70 mol % of dipalmitoylphosphatidylcholine, (2) from 10 to 70 mol % of distearoylphosphatidylcholine, (3) from 10 to 30 mol % of soya lecithin, wherein the sum of the constituents indicated under 1 to 3 must, in each case, be equal to 100 mol %.
Claim 2
Dependent Claim
62 words
Artificial surfactant characterised in that it consists essentially of a ternary mixture of: (1) from 10 to 70 mol % of dipalmitoylphosphatidylcholine, (2) from 10 to 70 mol % of distearoylphosphatidylcholine, (3) from 10 to 30 mol % of soya lecithin, wherein the sum of the constituents indicated under 1 to 3 must, in each case, be equal to 100 mol %.
Claim 3
Dependent Claim
27 words
Pharmaceutical composition containing the artificial surfactant according to claim 1 in the form of liposomes, which, pharmaceutical composition can be used for replacing deficient endogenous pulmonary surfactant.
Claim 4
Dependent Claim
21 words
Pharmaceutical composition according to claim 2 in the form of liposomes suspended in water or in a physiologically acceptable aqueous solution.
Claim 5
Dependent Claim
24 words
Pharmaceutical composition containing one or more compounds which can be used therapeutically and which contains as carrier an artificial surfactant according to claim 1.
Claim 6
Dependent Claim
20 words
Artificial surfactant of claim 1 in the form of liposomes optionally suspended in water or in a physiologically-acceptable aqueous solution.
Claim 7
Dependent Claim
30 words
Artificial surfactant according to claim 1, characterised in that it is composed of 40 mol % of dipalmitoylphosphatidylcholine, 40 mol % of distearoylphosphatidylcholine, and 20 mol % of soya lecithin.
Claim 8
Dependent Claim
27 words
Pharmaceutical composition containing the artificial surfactant according to claim 6 in the form of liposomes, which pharmaceutical composition can be used for replacing deficient endogenous pulmonary surfactant.
Claim 9
Dependent Claim
21 words
Pharmaceutical composition according to claim 7 in the form of liposomes suspended in water or in a physiologically acceptable aqueous solution.
Claim 10
Dependent Claim
24 words
Pharmaceutical composition containing one or more compounds which can be used therapeutically and which contains as carrier an artificial surfactant according to claim 6.
Claim 11
Independent Claim
36 words
A method for treating respiratory distress in neonates wherein endogenous pulmonary surfactant normally present is absent or deficient, comprising administering endotracheally an artificial surfactant consisting essentially of a ternary mixture of dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, and soya lecithin.
Claim 12
Independent Claim
36 words
A method for treating respiratory distress in neonates wherein endogenous pulmonary surfactant normally present is absent or deficient, comprising administering endotracheally an artificial surfactant consisting essentially of a ternary mixture of dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, and soya lecithin.
Claim 13
Dependent Claim
35 words
The method of claim 10 wherein the artificial surfactant comprises about 40 mol % of dipalmitoylphosphatidycholine, 40 mol % of distearoylphosphatidylcholine, and 20 mol % of soya lecithin and is in the form of liposomes.
Claim 14
Dependent Claim
61 words
The method of claim 10, wherein the artificial surfactant consists essentially of: (1) from 10 to 70 mol % of dipalmitoylphosphatidylcholine, (2) from 10 to 70 mol % of distearoylphosphatidylcholine, (3) from 10 to 30 mol % of soya lecithin, wherein the sum of the constituents indicated under 1 to 3 must, in each case, be equal to 100 mol %.
References Cited (Backward Citations)
DE2900300A1
Cited
US4310506A
Cited
US4312860A
Cited
EP0050793A1
Cited
US4394372A
Cited
EP0110498A1
Cited
US4515736A
Cited
US4673567A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-08-23 | 1992-02-22 | 1992-08-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-08-23 | 1996-02-22 | 1996-08-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-08-23 | 2000-02-22 | 2000-08-23 | $7700.00 | Window Closed / Lapsed |